FDA Approval Alert: The Need-to-Know | Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma

In May 2024, the FDA approved lisocabtagene maraleucel as a treatment for patients with relapsed/refractory mantle cell lymphoma.

FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma
FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma
Article
Jul 12, 2024 2:00 PM
Michael Wang, MD, spoke about the recent liso-cel approval in mantle cell lymphoma and the TRANSCEND trial.
Findings from the TRANSCEND NHL 001 trial support the FDA approval of lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma.
FDA Approves Liso-cel in Relapsed/Refractory Mantle Cell Lymphoma
Article
May 30, 2024 4:23 PM
Findings from the TRANSCEND NHL 001 trial support the FDA approval of lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma.